Biosimilar Conference | Pharmaceutical Conference | Upcoming Biosimilar Conference

Theme: Essential innovation in Pharma biosimilars

Biologicsmeet 2020

Biologics Meet

Renowned Speakers

Suliman Al-Fayoum
Al-Fayoumi Consulting USA
USA

Insang Lee
Divine Lab Co Ltd South Korea
South Korea

Kunihiko Furuzaw
Kunihiko Furuzaw GMP Consultant Japan
Japan

Anselmo J Otero-Gonzalez
Anselmo J Otero-Gonzalez University of Havana Cuba
Cuba

Fabiola Porta
Fabiola Porta University of Basel Switzerland
Switzerland

Margitta Dathe
Margitta Dathe Leibniz-Forschungsinstitut fÃ¼r Molekulare Pharmakologie Germany
Germany

Mikhail Durymanov
Mikhail Durymanov South Dakota State University USA
USA

Vladimir P. Torchilin
Vladimir P. Torchilin Northeastern University USA
USA

Biologicsmeet 2020

About conference

Biologics meet 2020 invites all participants from around the world to participate in the "World Congress on Biologics and Biosimilars" to be held on November 16-17, 2020 in Kyoto, Japan, and will cover all aspects of the pharmaceutical sciences, manufacturing, quality with a strong emphasis on originality and scientific quality.

Conference Series LLC LTD organizes 1000+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies and publishes 1000+ Open access journals which contain over 70000 eminent personalities, reputed scientists as editorial board members, 1200 Symposium & Workshops and 5 million followers. Conference Series Ltd invites all the participants across the globe to attend the “World Congress on Biologics and Biosimilars "

Biologics meet 2020 describes recent developments in the marketing and production of pharmaceutical drugs and contract manufacturing. A comprehensive knowledge of a scientific discipline that describes the effects of Biosimilars drug marketing and Biologics meet 2020 is now exploring the scope of Biosimilars drug marketing in the industry. Biologics meet 2020 provides detailed market, technology and industry analysis to help readers quantify and qualify the generic prescription market. Significant trends are identified and sales forecasts by product category and major national markets are based on industry sources and an assessment of the regulatory environment, health policies, demographics and other factors directly affecting the generic market. The wider economic environment is also taken into account.

Why attend Biologics meet 2020:

Keynote presentation along with interactions to galvanize the scientific community.

Workshop and symposiums to reach the largest assemblage of participants from the Pharma/Biotech community.

A wide track of exhibitors to showcase the new and emerging technologies.

Platform to global investment community to connect with stakeholders in Pharma/Biotech sector.

Young Scientist/ Investigators Award geared towards best budding young research

Links to the political marketing resources to expand your business and research network.

Triumph of Awards, Certificates recognizes your commitment to your profession to encourage the nascent research.

â€‹Target Audience:

Directors, CEO’s of Organizations
Business Development Managers
Chief Scientific Officers
R&D Researchers from Biosimilar and Biologics Industries
Professors, Associate Professors, Assistant Professors
PhD Scholars
Patent Attorneys
Intellectual Property Attorneys
Investment Analysts
Association, Association presidents and professionals
Noble laureates in Health Care and Medicine
Bio instruments Professionals
Bio-informatics Professionals
Software development companies
Research Institutes and members
Supply Chain companies
Manufacturing Companies
CRO and DATA management Companies
Training Institutes
Business Entrepreneurs

Biologics meet 2020 has everything you need:

Open Panel Discussions: Provide an open forum with experts from academia and business to discuss current challenges in Biosimilars & Biologics, where all participants can interact with the panel, followed by a Q & A session.

Speaker and poster presentations: Provide a platform for all academics and industry professionals to share their thoughts and research findings through a speech or poster presentation.

Editorial Board Meeting: Discussion on the growth and development of open access journals in Bioanalysis and Biomedicine, as well as the recruitment of committee members and reviewers to support the journal.

Roundtables: Provide a platform where industry professionals meet with academic experts.

More than 50 international organizations and pavilions will exhibit at Biologics meet 2020 pharma conference. Exhibitors will include equipment manufacturers and suppliers, system suppliers, finance and investment companies, research and development companies, developers projects, trade associations and government agencies.

In addition to products and services, you'll have access to valuable content, including keynote presentations, product demonstrations, and training sessions offered by industry leaders today.

The Biologics meet 2020 brings together everything you need, under one roof, to save you time and money. This is the event not to be missed!

A two-day rally that examines future market models, creative business methodologies and open doors to the development of moderate medicines. Pioneers in the pharmaceutical industry want substance and roundtable reviews to remain for systems administration and air. This meeting is officially the largest non-proprietary key meeting of the company and will provide members with a comprehensive overview of the business methodology for moderate medications.

Get your image before senior chiefs

Break into the lucrative Generic Medicines industry

Position your organization as an industry pioneer

Make deals leads and convey an arrival on venture

Connect with your objective market in the locale.

Sessions/Tracks

Track 1: Analytical Strategies of Biosimilar

Biologics and Biosimilar analysis make the one of the most important aspect on the development on biological products. The use of production technologies such as disposable and supply chain logistics can help companies such establish flexibility facility involved in biosimilar analytical methods.

Bio analytical methods include in all global events of biosimilars for example: GMP protein analysis, pre-clinical and clinical program, Bioassay for comparability and potency testing.

Pharmaceutical Societies in USA: International Biopharmaceutical Association, Consumer Healthcare Products Association (CHPA), Generic Pharmaceutical Association (GPhA), International Pharmaceutical Expedient Council, Pharmaceutical Research and Manufacturers of America (PhRMA) Synthetic Organic Chemical Manufacturers Association (SOCMA), Biotech Industry Association (BIO), Parenteral Drug Association (PDA), Chinese Biopharmaceutical Association, Pharma & Biopharma Outsourcing Association (PBOA), SAFE-BioPharma Association and The BioPharmaceutical Emerging Best Practices Association (BEBPA)

Pharmaceutical Societies in Europe: European Federation of Pharmaceutical Industries and Associations (EFPIA), European Biopharmaceutical Enterprises (EBE), European Association of Pharma Biotechnology, International Federation of Pharmaceutical Manufacturers & Associations, European Federation of Biotechnology, EuropaBio and European and Developing Countries Clinical Trials Partnership

Pharmaceutical Societies in Asia: The Hong Kong Association of the Pharmaceutical Industry, International Pharmaceutical Manufacturers Group, International Research-based Pharmaceutical Manufacturers Association, Japan Pharmaceutical Manufacturers Association, Korea Pharmaceutical and Bio-Pharma Manufacturers Association, Korean Research-based Pharmaceutical Industry Association, Organization of Pharmaceutical Producers of India, Pharmaceutical Association of Malaysia, Pharmaceutical and Healthcare Association of the Philippines, China Pharmaceutical Innovation & Research Development Association, Pharmaceutical Research & Manufacturers Association, R&D-based Pharmaceutical Association Committee, Singapore Association of Pharmaceutical Industries

Track 2: Emerging Biosimilars In Therapeutics

In the field of biologics, the new avenue has created towards clinicians because explorations have created for better disease management. In the treatment of ailments like psoriasis, rheumatic arthritis, certain cancer inflammation, bowel diseases etc. showed some good outcomes because of using biologics. Biosimilar insulins which are newly formed are likely to enter the insulin landscape as patents for major branded insulin products ready to expire in the next few years. The emerging biosimilar like filgrastim, peg filgrastim, recombinant blood products, therapeutic products vaccine biosimilar, anti-bodies growth hormones, biosimilar peptide, all these are used to sound knowledge on biosimilars development on drugs.

Track 3: Current Challenges in Developing Biosimilars

For the development of biological calls many changes may occur. Concepts of biologics with considerations at initial stages, clinical developments are essential at early. For the successful development of biologics follow on proper scientific and strategic approaches are need. Most probably, the drug safety factors and labelling requirements are the overcoming challenges and important in continue of late clinical steps. And now it is much required to develop a drug product in according to quality by design.

Track 4: Regulatory Approaches of Biosimilars

biosimilars is likewise called as nonspecific adaptation of biosimilars. The clinically idle compound is not withstanding with biosimilars but rather minor contrasts and profoundly like authorized item; additionally, there Presently a-days in pharmaceutical industry biosimilars is shaped has another buzz. Furthermore, these are no clinically important contrasts between the biologicals and the reference item as far as intensity, wellbeing and immaculateness. The worldview of customary generics to biosimilars, and different parts of Biosimilar endorsements. Also, these Biosimilars 2019 will give a phenomenal and overall chance to the researchers, accomplices and pharma pioneers from Biopharmaceutical and Biotechnology businesses to improve and to investigate the key market for Biosimilars and Biologics with an unmistakable photo of the administrative approach for biosimilars and biologics. The US biosimilars, European biosimilars, Canada biosimilars, UK biosimilars take a noteworthy part in cross the globe by 2019. Biosimilars development. And these biosimilar conferences will mainly focus on bio similar product development to deliver safe and successfully.

Track 5: Pharmacovigilance challenges in Biosimilars

Same proportion pharmacovigilance for biosimilars has comparatively more different from other products. Biosimilars 2019 session mainly look that have already been announced to include enhanced tracking and follow-up of post marketing surveillance issues, and on FDA initiative planned different changes in AERS, pilots of new developed post market strategies of drug-monitoring and ADR related problems. The guidelines of biosimilars for pharmacovigilance and pharma epidemiology are the points that shall be laid emphasis in the session In USA average annual income mostly spend on biologics comparing to generic drugs for example:16% on biologics and 3% on other drugs.

Track 6: BCS and IVIVC Based on Biosimilars

These Mainly discusses about different types of drugs and adsorption distribution metabolism excretion pathways. And This biosimilars includes, In vitro diffusion cells for dissolution testing in formulation development, The preclinical testing of ADME in INVITRO. The primary moto of this work was to suggest the biosimilars potential of biopharmaceutical classification system which are known to increase the dissolution. These insoluble drugs which is orally absorbed. These Aims at addressing all such challenges of the pharma formulation sector at biologics and biosimilars at 2019 conference. The solubility includes in biopharmaceutical classification.

Track 7: Globalization of Bio Similar

These tracks mainly deal with biosimilar meetings those who can attend by following biologics/protein/biosimilar product process science, New biosimilar development, portfolio Management, Reasearch&development, biosimilar market, business operations, scientific affairs. This track mainly discusses about Risk-sharing arrangement LATAM market for bio-similar adopting innovative mechanism for generic drugs impact on global bio similar market and cost and risk management.

Track 8: Clinical Development of Biosimilars

Risk Management, quality affairs, Case studies, clinical models, Transgenic animals Targeted cell-line development, clinical biosimilar tracks are major diseases of clinical trials. The pkd/docx studies toxicological studies and Aspects of genotoxicity tests. And These tracks are designed especially for those who are having more knowledge on clinical studies and clinicians’ prospects for biosimilars. These guidelines on the above-mentioned topics are also to be thrown effect upon at this biosimilars conference.

Track 9: Bioequivalence assessment

The active ingredient from the pharma product and its absorption into the systemic circulation is mainly focus on equivalence release. Bioequivalence assessment includes strategies of topical dosage forms and bio equivalence approaches for transdermal dosage form and assessment of respiratory dosage form.

Track 10: Biosimilars Research Pipeline

The biological medical product is a biosimilar manufactured by a different company by the copy of an original product. The original biosimilar innovator products are officially approved biosimilar can be manufactured when the originally product patient expire. This session shall be highly useful for the biosimilar industry researchers to update themselves on the latest research updates from all over the world. Not only these sessions and also there are many ways to find the exact place for all the biosimilar exhibitions associated with present generation of biosimilars and biologics.

Track 11: Intellectual Property Rights

That any pharma product has successfully pass through the regulatory affairs scanners before launched in the market need less to mention. Biosimilars and biologics are no exceptions. The companies developing these biosimilars and biologics apart from regulatory aspects tend to enjoy monopoly over their product. Intellectual Property Rights (IPR) and patents are ultimate tools to the biosimilar manufacturers for safeguarding their interests. 2016 was a record year for development of Biosimilars & biologics in US. In this year 16 IPR petition was filed. So, expected scenario of 2017 would be a boom in Biosimilar and biologics field.

Track 12: Brexit Effect on Biosimilar

The negative tendency of biosimilars Brexit impact. The hindrance towards the cost cutting approach taken by the NHS is a major setback towards approval and launch of biosimilars in market. With Britain being among foremost clinical preliminary focuses is claimed to see a diminishing in the eagerness of the makers and specialists to do any further preliminaries in Britain. Additionally, Brexit will cause the primary rationale of British Biosimilars Association (BBA) to fall back-which went for expanding the utilization of Biosimilars.

Track 13: Drug Delivery and Development

Medication Delivery Companies and Market session is starting to change for little, large, and medium scale pharmaceutical, Co biopharmaceutical Manufacturing and Industries, bland medications organizations, contract sedate conveyance organizations which can show from improvement to assembling. Tending to these dangers is an extraordinary test, because of the many-sided quality of the Clinical bio therapeutics themselves.

Track 14: Current Agency Expectations for Approval for Biosimilars

Biosimilars are a generally new subset of biopharmaceuticals, with the biotechnology business at last developing to such an extent that off-patent nonexclusive compose items progressively will enter real markets. Up until now, more than 20 biosimilars for a set number of reference items have been affirmed in realhttps://biologicsmeet.pharmaceuticalconferences.com/abstract-submission.php markets, principally the European Union. Just two items have been formally endorsed as biosimilars in the United States. The parent field of biopharmaceuticals itself keeps on displaying a poor supporting framework of data assets. Those biopharmaceutical and biosimilar data assets that do exist for the most part are restricted in number, assorted variety, and advancement.

Track 15: Biological Medicine:

Organic Medicine works with the science of the body and its regular recuperating capacities and in addition the otherworldly, passionate and physical parts of malady. Sickness implies that the body's direction isn't working legitimately and should be brought once again into its normal powerful state where the invulnerable framework is in full control. It in this manner searches for main drivers for the showing side effects of sickness the hidden elements making a man give a specific disease. These underlying drivers may comprise of a few elements which have developed after some time and can incorporate; consume less calories, sustenance sensitivities, intestinal unsettling influences, family history, push, ecological elements, substantial metals, dental issues , hyperacidity, injury, introduction to microscopic organisms or infections or electromagnetic aggravation.

Market Analysis

Biosimilars of Complex mab structure are expected to grow to a cumulative market size of ¥300b in the next three years in Japan. It will open doors for the first oncology biosimilar mAb in Japan after Remicade BS launch in 2014, while over the next 7 years it is anticipated to be worth a cumulative ¥600b.

In the last five years, most of the companies have some alliance in place for biosimilars, with most of the Japanese companies undertaking pacts with South Korean companies to ride on the back of biosimilar mab expertise. There is a trend of seeking out product specific alliances by most of the JP companies active in the BS space and to go step by step on these high risk/high return opportunities. Overall, in Japan's market, each opportunity has a different competitive landscape for itself, and some companies are looking for niche opportunities in biosimilar space as per their specialty therapy area- like ophthalmology BS (Lucentis), Enzyme therapy BS (JCR).

Biologics meet 2020 Market was worth USD 1.26 million in 2018 and estimated to be growing at a CAGR of 31.60%, to reach USD 4.99 million by 2023 Biosimilars are emerging as one of the most important sector in the healthcare industry. With increasing healthcare costs, biosimilars are being looked upon as an affordable treatment option. Growing economies are observing comprehensive growth in biosimilars industry from demanding clinical needs of therapeutics. Rise in GDP and healthcare expenditures, and the demand for cost effective therapeutics solution has resulted in the growth of this market. Biosimilars of Complex mAb structure are expected to grow to a cumulative market size of ¥300b in the next three years in Japan. It will open doors for the first oncology biosimilar mAb in Japan after Remicade BS launch in 2014, while over the next 7 years it is anticipated to be worth a cumulative ¥600b.

Pharma Biosimilars 2019

We gratefully thank all our wonderful Speakers, Conference Attendees, Students, Media Partners for making Pharma Biosimilars 2019 Conference the best ever and memorable!

The International Conference on Biosimilars & Pharmaceuticals, hosted by the Conferenceseries LLC was held during February 28-March 01, 2019 Osaka, Japan based on the theme “Essential innovation in Pharma biosimilars’’. Benevolent response and active participation was received from the Organizing Committee Members along with Scientists, Researchers, Students and leaders from various fields of Pharmaceutical Science, who made this event a grand success.

The Conference focused on recent developments in the Pharmaceutical Science sector and the meeting engrossed in knowledgeable discussions on subjects like:

Analytical Strategies of Biosimilar
Emerging Biosimilars In Therapeutics
Current Challenges in Developing Biosimilars
Regulatory Approaches of Biosimilars
Pharmacovigilance challenges in Biosimilars
BCS and IVIVC Based on Biosimilars
Globalization of Bio Similar
Clinical Development of Biosimilars
Bioequivalence assessment
Biosimilars Research Pipeline
Intellectual Property Rights
Brexit Effect on Biosimilar
Drug Delivery and Development
Current Agency Expectations for Approval for Biosimilars
Biological Medicine

The conference was initiated with the Honourable presence of the Keynote forum:

Session Chair: Lincy Joseph, Pushpagiri College of Pharmacy, India

Title: Challenges in developing biosimilars

Subir K Basak, International Finance Corporation, USA

Title: Water as an alternative medicine in cell biology

Insang Lee, Divine Lab Co Ltd, South Korea

Title: Risk base Technical transfer in pharmaceutical manufacturing

Kunihiko Furuzaw, GMP Consultant, Japan

Title: Pharmacological screening of oxazines for epilepsy

Mathew George, Pushpagiri College of Pharmacy, IndiaHouston, USA

Poster Presentation:

Title: Navigating the biosimilar journey from bench to market: A general overview and case studiesSuliman Al-Fayoumi, Al-Fayoumi Consulting, USA

Title: Anti-MRSA activity of cationic lipid carriers in combination with oxacillin for eradicating skin Infection

Jia-You Fang, Chang Gung University, Taiwan

Title: Screening of novel oxazepines for anticonvulsant effect

Lincy Joseph, Pushpagiri College of Pharmacy, India

Title: Antibacterial activity of collagen/gelatin/sodium alginate biomaterial with liposomes

immobilized releasing antibiotics

Ming-Cheng Chang, Institute of Nuclear Energy Research, Taiwan

Video Presentation:

Title: Design of bioavailability and bioequivalence studies through PK-Stat approach

Jaganmohan Somagoni, ClinSync Clinical Research Private Limited, India.

Conferenceseries LLC offers its heartfelt appreciation to organizations such as Go EVNTS & Bentham Science and other eminent personalities who supported the conference by promoting in various modes online and offline which helped the conference reach every nook and corner of the globe. Conferenceseries LLC also took privilege to felicitate the Keynote Speakers, Organizing Committee Members and Chairs who supported this event.

With the grand success of Pharma Biosimilars 2019, Conferenceseries LLC is proud to announce the "World Congress on Biologics and Biosimilars" to be held during November 16-17, 2020 at Kyoto, Japan based on the Theme: Organic products meet: current scenario and future prospects Pharmaceutical Sciences.

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	November 16-17, 2020
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed
Poster Opportunity Closed	Click Here to View

World Congress on Biologics and Biosimilars November 16-17, 2020 Kyoto, Japan

Recommended Global Pharmaceutical Sciences Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links

Renowned Speakers

Biologicsmeet 2020

Conference Highlights

To Collaborate Scientific Professionals around the World

Useful Links

Special Issues